瑞波西利一线治疗绝经前妇女HR+/HER2-晚期或转移性乳腺癌的药物经济学评价

张森, 王洁, 李赛男, 王美祺, 巨英博, 王明霞, 贾才凤

Pharmacoeconomic evaluation of ribociclib as first-line treatment in premenopausal women with HR+/HER2- advanced or metastatic breast cancer

ZHANG Sen, WANG Jie, LI Sai-nan, WANG Mei-qi, JU Ying-bo, WANG Ming-xia, JIA Cai-feng

中国新药杂志 . 2025, (16): 1784 -1792 . DOI: 10.20251/j.cnki.1003-3734.2025.16.014